A control study for sertraline and agomelatine on insomnia symptoms in patients with depression

The effects of sertraline and agomelatine on insomnia symptoms in patients with depression

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800020182

Enrollment

Unknown

Registered

2018-12-19

Start date

2018-12-12

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dpression

Interventions

agomelatine:agomelatine 25-75mg per day before sleep

sertraline:sertraline 50-200mg per day before sleep

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years Female or male patients with depression; 2. Dextromanuality; 3. HAMD scores =7.

Exclusion criteria

Exclusion criteria: 1. Suicide history, allergic history for the investigated drug; 2. Combined severe or unstable somatic disease; 3. The patients were diagnosed as epilepsy, bipolar disorder, drug or alcohol dependence; 4. The patients had accepted MECT now or took antidepressants/ antipsychotics/ emotional stabilizer during last 30 days; 5. The patients had some contraindications that limit them from taking MR examination; 6. Pregnant or lactational patients; 7. Epilepsy history, COPD, restless legs syndrome, periodic legs, apnea; 8. NMS history; 9. Treatment resistant depression; 10. Contraindications for MRI scan.

Design outcomes

Primary

Measure	Time frame
PSG;serum melatonin;serum BDNF;PSQI;	—

Secondary

Measure	Time frame
HAMD;SDS;adverse reactions;	—

Countries

China

Contacts

Public ContactPu Zhengping

Kangci Hospital of Jiaxing

440391221@qq.com+86 13806717447

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026